CCX832
From Self-sufficiency
Please help improve this article by expanding it. Further information might be found on the talk page. (June 2010) |
 | This article relies largely or entirely upon a single source. Please help improve this article by introducing citations to additional sources. Discussion about the problems with the sole source used may be found on the talk page. (June 2010) |
CCX832 is an orally active molecule antagonist of chemerin at the chemokine receptor CMKLR1(ChemR2). ChemoCentryx a pharmaceutical firm based in California announced in April 2010 that they were successful in developing this medication in alliance with GlaxoSmithKline(GSK).[1]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />- ↑ "ChemoCentryx Identifies Novel Small Molecule ChemR23 Antagonist for the Treatment of Inflammatory Diseases". Press Release. ChemoCentryx. 2010-04-10.
